

Monash IVF Group Limited (ASX:MVF)

11 November 2025

Monash IVF Group appoints Associate Professor Victoria Atkinson as Managing Director and Chief Executive Officer

Monash IVF Group Ltd (ASX: MVF), a leading provider of assisted reproductive services (ARS) and specialist women's' imaging and diagnostic services in Australia, Singapore, Indonesia and Malaysia, is pleased to announce the appointment of Dr Victoria Atkinson as Managing Director and Chief Executive Officer (CEO) effective from 18 May 2026.

Dr Atkinson is a distinguished healthcare executive with over 30 years of experience spanning clinical, operational, and governance leadership across Australia's public, private and not-for-profit health sectors. Victoria's current role is the Chief Medical Officer at Healthscope, where she oversees clinical strategy, governance, risk, medical affairs and medico-legal portfolios across a network of 36 hospitals, 15 intensive care units and 11 mental health facilities nationwide.

Prior to Healthscope, Dr Atkinson was the national Chief Medical Officer and Group General Manager of Clinical Governance for St Vincent's Health Australia and previously, was the Director Medical Governance at Melbourne health, combining this with an active clinical role.

Dr Atkinson is a cardiothoracic surgeon by training, with a Masters in Health Management. Dr Atkinson is currently a Board Member of the McGrath Foundation Ltd, the Medical Indemnity Protection Society and Opal HealthCare.

MVF Chairman Richard Davis welcomed Dr Atkinson to the Monash IVF Group Board. He said *"The Board has undertaken a thorough search process and the Board is impressed that Victoria brings a unique combination of clinical and financial experience to the role. We are looking forward to Victoria bringing that focus to our people, our doctors and our patients"*.

Further to the appointment of the Managing Director and CEO, Monash IVF Group advises that Mr Andrew MacLachlan finishes his interim role and term as Chief Financial Officer on 21 November 2025. A search is underway for a replacement while Mr Malik Jainudeen continues as Acting Chief Executive Officer until Dr Atkinson commences in 2026.

Material Terms of Employment

In accordance with ASX Listing Rule 3.16.4, the material terms of Dr Atkinson's employment agreement are summarised below:

Term	Detail
Position	Managing Director and CEO
Commencement Date	18 May 2026
Total Fixed Remuneration	\$800,000 per annum including superannuation
Short-Term Incentive	The CEO and MD can earn an annual incentive of 50% of their fixed remuneration if they meet financial and non-financial targets.
Long-Term Incentive	The CEO and MD can earn an annual incentive of 50% of their fixed remuneration if they meet financial and non-financial targets.
Term/Notice	No Fixed Term 6 months notice and 6 months restraint

Authorised by the Board of Directors.

For further information please contact:

Malik Jainudeen

Acting Chief Executive Officer & Company

Secretary

Monash IVF Group

T: +61 3 9420 8235